Posts

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Hansoh Hits Phase III SCLC Goal

on

Sanofi floats flu shot marketing pledges to pacify EU antitrust probe

on

EU investigates Sanofi over alleged smear campaign against rival flu vaccine Fluad

on

Sanofi's R&D chief Ashrafian exits as new CEO Garijo seeks to fix pipeline with former Roche executive Fontoura

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

on

KOL Bulletin: Sanofi's Lunskeimig Shows Promise in Respiratory Diseases but Faces Challenges Against Dupixent and Anti-TSLP Competitors

on

Sanofi CFO Defends Hudson's Dupixent Legacy While Acknowledging R&D Setbacks

on

Sanofi's Tolebrutinib Receives EMA Backing for Nonrelapsing Progressive MS Despite FDA Rejection

on

Sanofi's Dupixent LCM Strategy Gains Prominence Amid Q1 2026 Success and Patent Defense Plans

on

Sanofi Defends Belén Garijo's CEO Appointment Amid R&D and Immunology Focus

on

FDA Delays Decision on Sanofi's Subcutaneous Sarclisa to July 23, 2026

on

Sanofi's Bispecific Lunskeimig Succeeds in Asthma and Sinusitis Phase 2 Trials, Falls Short in Eczema

on

Sanofi's Bispecific Scores Double Respiratory Phase 2 Wins but Flunks Eczema Study

on

Kakao Healthcare and Sanofi Partner to Harness Medical Data for AI Solutions

on